We are monitoring the impact of COVID-19 on Latin America Cardiovascular Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date October, 2021
ID: 12292
Share on
Share on

Latin America Cardiovascular Drugs Market Research Report - Segmented By Drugs Type, Disease indication, End-Users, and Country (Brazil, Argentina, Chile, Mexico and Rest of Latin America) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast | 2021 to 2026

Pulished: October, 2021
ID: 12292
Pages: 137

Latin America Cardiovascular Drugs Market Size (2021 to 2026)

The size of the Latin America cardiovascular drugs market is estimated to be growing at a CAGR of 6.86% from 2021 to 2026. The market was valued at USD 7.28 billion in 2021 and is predicted to be worth USD 10.15 billion by 2026.

Cardiovascular drugs are agents that are used to treat diseases associated with the circulatory system, including blood clots, stroke, coronary heart disease, hypertension/ hypotension, arrhythmias, high cholesterol, and heart failure. These drugs are used to treat cardiovascular disease includes coronary heart disease, hyperlipidemia, myocardial infarction, blood vessel disorders, etc.

Cardiovascular disease (CVD) is one of the major chronic diseases affecting people across the world. Cardiovascular diseases include an array of disorders such as hypertensive heart disease, rheumatic heart disease, cerebrovascular disease, ischemic heart disease, and inflammatory heart disease. According to the World Health Organization report, more than 18 million people have died from cardiovascular disease in the year 2015, and cardiovascular diseases accounted for 33% of all deaths across the globe.

Factors such as sedentary lifestyle, excessive alcohol consumption, stress, drug abuse, and smoking are factors responsible for the increase in the number of cardiovascular disorders in the population. CVDs were responsible for around 12% of all hospitalizations in Brazil between 20010 and 2020. With the growing age and increase in the prevalence of chronic diseases such as diabetes and their complications, the rate of CVS disease has gone up tremendously. The cerebrovascular disease affects the blood vessels in the brain and can lead to stroke.  In recent times, the increasing prevalence of CVS, CNS diseases, and a large number of drugs are the major drivers of the Latin America cardiovascular drugs market. According to the Center for Disease Control and Prevention, approximately 60,000 people have a stroke each year.

The decreasing death rates and the increasing number birth rate and improving healthcare infrastructure are also contributing to the growth of the Latin America cardiovascular drugs market. The increasing number of diabetic patients has immense potential for the growth of the global cardiovascular drugs market. A high number of drug approvals are critical to the growth of the Latin America cardiovascular drug market, which has increased the awareness of cardiovascular health in the region and this corresponds with the increase in frequent product launches.

However, Many cardiovascular drugs lose their exclusivity and patents and face market withdrawal, this is owing to the constant development and research of better drugs with lesser side effects in the market. This factor has given rise to the availability of many products in the market, which negatively affects the overall growth of the Latin America cardiovascular drugs market for the projected period.

This research report on the Latin America cardiovascular drugs market has been segmented and sub-segmented into the following categories:

By Drug Type:

  • Antihypertensive
  • Antihyperlipidemic
  • Anticoagulants
  • Antiplatelet Drugs
  • Others

By Disease Indication:

  • Hypertension
  • Hyperlipidemia
  • Coronary Artery Disease
  • Arrhythmia
  • Others

By End-Users:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Country:

  • Brazil
  • Argentina
  • Chile
  • Mexico
  • Rest of Latin America

The Latin America cardiovascular drug market is expected to be dominated by Brazil during the forecasted period. The market is anticipated to grow at an impressive CAGR of 3.6%. The main factors that are attributed to growth are stress, lack of a healthy diet, anxiety, and genetic predilection for cardiac disorders, and other chronic diseases such as diabetes and obesity. According to the American Heart Association, nearly 55 million people suffered from cardiovascular disease, of which coronary artery disease was the leading cause of death, attributed to the increased intake of fatty and junk food in recent times, which stimulates the market.

Mexico is anticipated to have a high CAGR growth owing to the increased prevalence of multiple cardiovascular diseases such as coronary artery disease, stroke, and atrial fibrillation in the region. Low wages and the availability of skilled labor have encouraged international companies to invest in Mexico. Moreover, increased medical tourism in the region is also supporting the growth of the cardiovascular drugs market in the region. In 2015, CVD was responsible for 30% of all deaths, with ischemic heart disease (30%) and cerebrovascular disease (30%) being the leading causes of CVD. There were a total of 11,444,821 CVD hospitalizations recorded between 2010 and 2017. People between the ages 50 to 79 years were the most affected. The number of recorded deaths from any cardiovascular disease was the highest in Mexico mainly due to the developing healthcare system and poor reimbursement policies in the region.

KEY MARKET PLAYERS:

Merck & Co, Sanofi S.A., Pfizer Inc., Bristol-Myers Squibb Company, and Novartis AG are a few of the noteworthy companies operating in the Latin America cardiovascular drugs market.

1. Introduction                                   

            1.1 Market Definition            

            1.2 Scope of the report                     

            1.3 Study Assumptions                      

            1.4 Base Currency, Base Year and Forecast Periods             

2. Research Methodology                             

            2.1 Analysis Design                

            2.2 Research Phases              

                        2.2.1 Secondary Research     

                        2.2.2 Primary Research          

                        2.2.3 Data Modelling 

                        2.2.4 Expert Validation          

            2.3 Study Timeline                 

3. Report Overview                            

            3.1 Executive Summary                     

            3.2 Key Inferences                 

4. Market Dynamics                           

            4.1 Impact Analysis                

                        4.1.1 Drivers  

                        4.1.2 Restraints          

                        4.1.3 Opportunities   

            4.2 Regulatory Environment              

            4.3 Technology Timeline & Recent Trends                

5. Competitor Benchmarking Analysis                                  

            5.1 Key Player Benchmarking            

                        5.1.1 Market share analysis   

                        5.1.2 Products/Service          

                        5.1.3 Regional Presence        

            5.2 Mergers & Acquisition Landscape                       

            5.3 Joint Ventures & Collaborations              

6. Market Segmentation                                

            6.1 Latin America Cardiovascular Drugs Market – By Drug Type:                

                        6.1.1  Antihypertensive         

                        6.1.2 Antihyperlipidemic       

                        6.1.3 Anticoagulants  

                        6.1.4 Antiplatelet Drugs        

                        6.1.5    Others

                        6.1.6 Market Size Estimations & Forecasts (2021-2026)      

                        6.1.7 Y-o-Y Growth Rate Analysis      

                        6.1.8 Market Attractiveness Index    

            6.2 Latin America Cardiovascular Drugs Market – By Disease Indication:               

                        6.2.1    Hypertension 

                        6.2.2      Hyperlipidaemia       

                        6.2.3 Coronary Artery Disease           

                        6.2.4 Arrhythmia       

                        6.2.5 Others   

                        6.2.6 Market Size Estimations & Forecasts (2021-2026)      

                        6.2.7 Y-o-Y Growth Rate Analysis      

                        6.2.8 Market Attractiveness Index    

            6.3 Latin America Cardiovascular Drugs Market – By End-Users:                

                        6.3.1 Hospital Pharmacies     

                        6.3.2  Retail Pharmacies        

                        6.3.3 Online Pharmacies        

                        6.3.4    Others

                        6.3.5 Market Size Estimations & Forecasts (2021-2026)      

                        6.3.6 Y-o-Y Growth Rate Analysis      

                        6.3.7 Market Attractiveness Index    

7. Geographical Landscape                            

            7.1 Latin America                   

                        7.1.1 By Country        

                                    7.1.1.1 Brazil

                                    7.1.1.2 Argentina

                                    7.1.1.3 Mexico

                                    7.1.1.4 Rest of Latin America

                        7.1.2 By Drug Type:   

                        7.1.3 By Disease Indication:  

                        7.1.4 By End-Users:   

8. Key Player Analysis                        

            8.1 Merck & Co                      

                        8.1.1 Business Description    

                        8.1.2 Products/Service          

                        8.1.3 Financials          

                        8.1.4 SWOT Analysis  

                        8.1.5 Recent Developments  

                        8.1.6 Analyst Overview          

            8.2 Sanofi S.A.            

            8.3 Pfizer Inc.             

            8.4 Bristol-Myers Squibb Company               

            8.5 Novartis AG                      

9. Market Outlook & Investment Opportunities                               

10.Appendix                           

            List of Tables              

            List of Figures  

  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and also identify the areas that are still untapped. 

  • The segment-level analysis in terms of drug type, disease indication, end-users, and region along with market size forecasts and estimations to detect key areas of industry growth in detail.

  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics.

  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis.

  • Study the microenvironment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development.

  • A comprehensive list of key market players along with their product portfolio, current strategic interests, essential financial information, legal issues, SWOT analysis, and analyst overview to study and sustain the market environment.

  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies, and recent developments in the market by the major companies

  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions.

  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations with a strong financial foothold in the market.

  1. Latin America Cardiovascular Drugs Market By Drug Type, From 2021 to 2026 ( USD Billion )

  2. Latin America Antihypertensive Market By Region, From 2021 to 2026 ( USD Billion )

  3. Latin America Antihyperlipidemic Market By Region, From 2021 to 2026 ( USD Billion )

  4. Latin America Anticoagulants Market By Region, From 2021 to 2026 ( USD Billion )

  5. Latin America   Antiplatelet Drugs Market By Region, From 2021 to 2026 ( USD Billion )

  6. Latin America Others Market By Region, From 2021 to 2026 ( USD Billion )

  7. Latin America Cardiovascular Drugs Market By Disease Indication, From 2021 to 2026 ( USD Billion )

  8. Latin America Hypertension Market By Region, From 2021 to 2026 ( USD Billion )

  9. Latin America Hyperlipidaemia Market By Region, From 2021 to 2026 ( USD Billion )

  10. Latin America  Coronary Artery Disease Market By Region, From 2021 to 2026 ( USD Billion )

  11. Latin America   Arrhythmia Market By Region, From 2021 to 2026 ( USD Billion )

  12. Latin America   Others Market By Region, From 2021 to 2026 ( USD Billion )

  13. Latin America Cardiovascular Drugs Market By End-Users, From 2021 to 2026 ( USD Billion )

  14. Latin America  Hospital Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )

  15. Latin America Retail Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )

  16. Latin America    Online Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )

  17. Latin America Others Market By Region, From 2021 to 2026 ( USD Billion )

  18. Brazil Cardiovascular Drugs Market By Drug Type, From 2021 to 2026 ( USD Billion )

  19. Brazil Cardiovascular Drugs Market By Disease Indication, From 2021 to 2026 ( USD Billion )

  20. Brazil Cardiovascular Drugs Market By End-Users, From 2021 to 2026 ( USD Billion )

  21. Argentina Cardiovascular Drugs Market By Drug Type, From 2021 to 2026 ( USD Billion )

  22. Argentina Cardiovascular Drugs Market By Disease Indication, From 2021 to 2026 ( USD Billion )

  23. Argentina Cardiovascular Drugs Market By End-Users, From 2021 to 2026 ( USD Billion )

  24. Mexico Cardiovascular Drugs Market By Drug Type, From 2021 to 2026 ( USD Billion )

  25. Mexico Cardiovascular Drugs Market By Disease Indication, From 2021 to 2026 ( USD Billion )

  26. Mexico Cardiovascular Drugs Market By End-Users, From 2021 to 2026 ( USD Billion )

  27. Rest of Latin America Cardiovascular Drugs Market By Drug Type, From 2021 to 2026 ( USD Billion )

  28. Rest of Latin America Cardiovascular Drugs Market By Disease Indication, From 2021 to 2026 ( USD Billion )

  29. Rest of Latin America Cardiovascular Drugs Market By End-Users, From 2021 to 2026 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample